The Latest Breaking News from Immunovant

Immunovant Inc (NASDAQ:IMVT) has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease (TED).  Immunovant expects to initiate its Phase 3 TED program in 2H of 2022 and is expected to enroll about 100 subjects for each trial.  Topline…

  Immunovant (NASDAQ:IMVT) reported its Q3 earnings results on Friday, February 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.